Daily semaglutide pill shown to curb heavy drinking in clinical trial

A clinical trial found that people with alcohol use disorder who took oral semaglutide — the active ingredient in GLP-1 drugs — showed significant improvements in drinking behaviour compared to those on placebo. Participants recorded reductions in heavy drinking across multiple measures. The results mark a promising new application for the GLP-1 drug class in treating addiction.